公开(公告)号：US09458236B2

公开(公告)日：2016-10-04

申请号：US14055222

申请日：2013-10-16

Applicant: GENMAB A/S

Inventor： Jan G. J. Van De Winkel ,  Marcus Antonius Van Dijk ,  Edward Halk ,  Arnout F. Gerritsen ,  Jørgen Petersen ,  Ole Baadsgaard

IPC: A61K39/395 ,  C07K16/28 ,  C07H21/04 ,  G01N33/53 ,  A61K45/06 ,  A61K47/48 ,  G01N33/569 ,  A61K39/00

CPC classification number: C07K16/2863 ,  A01K2217/05 ,  A01K2217/075 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/56966

Abstract: Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

公开(公告)号：US20160237161A1

公开(公告)日：2016-08-18

申请号：US14990869

申请日：2016-01-08

Applicant: GENMAB A/S

Inventor： Michel DE WEERS ,  Tim WALSETH ,  Jan VAN DE WINKEL ,  Tom VINK ,  Paul PARREN

IPC: C07K16/28 ,  A61K45/06 ,  G01N33/573 ,  A61K39/395

CPC classification number: C07K16/2878 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/2896 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/75 ,  C07K2317/76 ,  G01N33/573 ,  G01N2333/91148

Abstract: Isolated monoclonal antibodies which bind to human CD38 and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies.

公开(公告)号：US20160046727A1

公开(公告)日：2016-02-18

申请号：US14830336

申请日：2015-08-19

Applicant: GENMAB A/S

Inventor： Aran Frank LABRIJN ,  Joyce I. MEESTERS ,  Ewald T. J. VAN DEN BREMER ,  Joost J. NEIJSSEN ,  Patrick VAN BERKEL ,  Bart DE GOEIJ ,  Tom VINK ,  Jan VAN DE WINKEL ,  Janine SCHUURMAN ,  Paul PARREN

IPC: C07K16/40 ,  G01N33/68 ,  C07K16/28

CPC classification number: C07K16/468 ,  A61K2039/505 ,  C07K16/1063 ,  C07K16/2809 ,  C07K16/2863 ,  C07K16/2887 ,  C07K16/32 ,  C07K16/40 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/41 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/55 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94 ,  G01N33/6854

Abstract: Novel heterodimeric antibody-Fc-containing proteins, such as bispecific antibodies, and novel methods for producing such proteins

Abstract translation: 新型异二聚抗体-Fc的蛋白质，例如双特异性抗体，以及用于产生这种蛋白质的新方法

公开(公告)号：US20140348833A1

公开(公告)日：2014-11-27

申请号：US14199391

申请日：2014-03-06

Applicant: GENMAB A/S

Inventor： Jan VAN DE WINKEL ,  Paul PARREN ,  Willem Karel BLEEKER ,  Klaus EDVARDSEN ,  Jeroen Lammerts VAN BUEREN ,  Thomas VALERIUS ,  Michael DECHANT ,  Wencke WEISNER ,  Sven BERGER

IPC: C07K16/40 ,  G01N33/573 ,  C07K16/46

CPC classification number: C07K16/40 ,  A61K2039/505 ,  A61K2039/507 ,  C07K16/2863 ,  C07K16/44 ,  C07K16/468 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/573

Abstract: The invention relates to novel methods for the treatment of tumors, comprising administration of a bispecific antibody or a combination of two or more non-cross-blocking antibodies that recognize the same target antigen or antigenic complex. In particular, the invention relates to a method for inducing complement-mediated cell killing in the treatment of a tumor, said method comprising combined administration, to a human being in need thereof, of a first antibody and a second antibody, wherein said first antibody binds EGFR, said second antibody binds EGFR, said first and second antibody are non-cross-blocking, and the dosage regimen is such that CDC is obtained at the tumor site.

Abstract translation: 本发明涉及用于治疗肿瘤的新方法，包括施用双特异性抗体或两种或多种识别相同靶抗原或抗原复合物的非交叉阻断抗体的组合。 特别地，本发明涉及用于诱导补体介导的细胞杀伤治疗肿瘤的方法，所述方法包括向有需要的人共同施用第一抗体和第二抗体，其中所述第一抗体 结合EGFR，所述第二抗体结合EGFR，所述第一和第二抗体是非交叉阻断的，并且所述给药方案使得在肿瘤部位获得CDC。

公开(公告)号：US20140141006A1

公开(公告)日：2014-05-22

申请号：US14055222

申请日：2013-10-16

Applicant: Genmab A/S

Inventor： Jan G. J. VAN DE WINKEL ,  Marcus Antonius VAN DIJK ,  Edward HALK ,  Arnout F. GERRITSEN ,  Jørgen PETERSEN ,  Ole BAADSGAARD

IPC: C07K16/28 ,  G01N33/569 ,  A61K45/06 ,  A61K39/395 ,  A61K47/48

CPC classification number: C07K16/2863 ,  A01K2217/05 ,  A01K2217/075 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/56966

Abstract: Isolated human monoclonal antibodies which specifically bind to human EGFR, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract translation: 公开了与人EGFR特异性结合的分离的人单克隆抗体以及相关的基于抗体的组合物和分子。 人抗体可以通过经历V-D-J重组和同种型转换能够产生人单克隆抗体多重同种型的转染瘤或非人转基因动物例如转基因小鼠产生。 还公开了包含人抗体，非人转基因动物和产生人抗体的杂交瘤的药物组合物，以及使用人抗体的治疗和诊断方法。

公开(公告)号：US20040208873A1

公开(公告)日：2004-10-21

申请号：US10738120

申请日：2003-12-16

Applicant: MEDAREX, INC. ,  GENMAB A/S

Inventor： Jessica Teeling ,  Paul Parren ,  Ole Baadsgaard ,  Debra Hudson ,  Jorgen Petersen

IPC: A61K039/395 ,  C07K016/24

CPC classification number: C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/4241 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/92 ,  G01N33/6869

Abstract: Isolated human monoclonal antibodies which bind to IL-8 (e.g., human IL-8) are disclosed. The human antibodies can be produced in a hybridoma, transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals, hybridomas, and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract translation: 公开了与IL-8结合的分离的人单克隆抗体（例如人IL-8）。 人抗体可以通过进行V-D-J重组和同种型转换，在能够产生人单克隆抗体多重同种型的杂交瘤，转染瘤或非人转基因动物例如转基因小鼠中产生。 还公开了包含人抗体，非人转基因动物，杂交瘤和产生人抗体的转染瘤的药物组合物，以及使用人抗体的治疗和诊断方法。

公开(公告)号：US20240409656A1

公开(公告)日：2024-12-12

申请号：US18664772

申请日：2024-05-15

Applicant: GENMAB A/S

Inventor： Nurgul KILAVUZ ,  Mariana SACCHI

IPC: C07K16/28 ,  A61K39/00

Abstract: The present invention relates to improved methods for reducing cytokine release syndrome following interruption of the epcoritamab dosing schedule for the treatment of CD20 B-cell expressing cancers.

公开(公告)号：US20240409653A1

公开(公告)日：2024-12-12

申请号：US18698354

申请日：2022-10-05

Applicant: GENMAB A/S ,  BIONTECH SE ,  MSD INTERNATIONAL BUSINESS GMBH

Inventor： Alexander MUIK ,  Kristina NÜRMBERGER ,  Nora PENCHEVA ,  Maria N. JURE-KUNKEL ,  Ugur SAHIN

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: The present disclosure relates to combination therapy using a binding agent that binds to human PD-L1 and to human CD 13 7 in combination with pembrolizumab to reduce or prevent progression of a tumor or treating cancer.

公开(公告)号：US20240400703A1

公开(公告)日：2024-12-05

申请号：US18660847

申请日：2024-05-10

Applicant: Genmab A/S ,  BioNTech SE

Inventor： Kristel Kemper ,  Maarten van der Kroef ,  Dennis Verzijl ,  Andrea Gorlani ,  Pauline Linda de Goeje ,  Lars Guelen ,  David Satijn ,  Esther C. W. Breij ,  Ugur Sahin ,  Sina Fellermeier-Kopf ,  Maren Köhne

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: The present invention relates to antibodies capable of binding to human OX40 and to variants thereof comprising a modified Fc region comprising at least one mutation that enhances the Fc-Fc interaction of the antibody and at least one mutation that reduces the Fc effector functions of the antibody. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.

公开(公告)号：US20240254252A1

公开(公告)日：2024-08-01

申请号：US17259342

申请日：2019-07-15

Applicant: GENMAB A/S

Inventor： Bart E. C. G. DE GOEIJ ,  Grietje ANDRINGA ,  Frank BEURSKENS ,  Janine SCHUURMAN ,  David SATIJN ,  Tahamtan AHMADI

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/02

CPC classification number: C07K16/2896 ,  A61P35/02 ,  A61K2039/505 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76

Abstract: Antibody variants for therapeutic use involving trogocytosis-mediated reduction of CD38 on CD38-expressing immunosuppressive cells; particularly CD38 antibody variants comprising one or more mutations in the Fc region, such a mutation in one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein the amino 5 acid residues are numbered according to the EU index.